BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Contract Services

Biogen to acquire full ownership of Samsung Bioepis

Agreement with Biogen to buyout Biogen's (50% -1 share) stake in Samsung Bioepis Joint Venture for up to USD $2.3 billion Transaction projected to ...

January 28, 2022 | News

GenScript ProBio initiates a CDMO Contract For Next-Generation CD47 Antibody with InnoBation Bio

InnoBation Bio, led by Seung-gu Kim (CEO), is a biopharmaceutical company specializing in the development of biomarkers, Chimeric Antigen Receptor (CAR) T ...

January 26, 2022 | News

WuXi STA Launches its First Parenteral Formulation Manufacturing Line

The industry-leading automatic parenteral filling line features multiple filling modules and a built-in lyophilizer to fill vials, syringes, and ...

January 24, 2022 | News

GenScript ProBio to Expand Commercial cGMP Plasmid and Viral Vector

On January 19, 2022, GenScript ProBio broke ground for the construction of its newest plasmid and viral vector manufacturing facility, a 34,000-square...

January 21, 2022 | News

Vetter's new clinical manufacturing site now officially authorized

Important milestone reached for the new site Additional filling capacities for early-stage clinical development First customer audits already completed...

January 20, 2022 | News

Avance Clinical Announces Major PE Investment for US Expansion at Biotech Showcase 2022

Avance Clinical is taking meetings with biotechs to discuss the benefits of conducting trials in Australia, including no IND requirement and an attractive ...

January 18, 2022 | News

WuXi Biologics completes the first GMP inspection in 2022

WuXi Biologics a global company with leading open-access biologics technology platforms, announced that it has completed a remote GMP inspection by&n...

January 18, 2022 | News

Samsung Biologics Shares Strategic Roadmap for Sustainable Growth

During the main track presentation today, John Rim, President and CEO of Samsung Biologics, addressed the company's vision for 2022 and business goals...

January 13, 2022 | News

Clario and XingImaging expand partnership to deliver PET imaging clinical trials in China

Clario, formerly ERT and Bioclinica, and XingImaging joined forces in 2018 to support multi-center clinical trials requiring PET for eligibility and drug e...

January 12, 2022 | News

Cellusion Raises 1.1B JPY to Advance Japan and Global Clinical Trials

Cellusion Inc., a regenerative medicine startup aiming to solve the global Corneal transplant waiting list problem with a unique differentiation induction ...

January 10, 2022 | News

Definitive Agreement to Acquire Exelead will Strengthen Merck’s CDMO Offering for mRNA

Merck, a leading science and technology company, has signed a definitive agreement to acquire Exelead, a biopharmaceutical contract development and manufac...

January 07, 2022 | News

WuXi Biologics, ImmuneOncia Sign MOU for Development and Manufacturing of Anti-PD-L1/CD47 Bispecific Antibody

Within the partnership, ImmuneOncia will have access to WuXi Biologics' integrated services in cell line development, cell culture development, biologics m...

December 28, 2021 | News

Curia Unveils Comprehensive mRNA Solution

Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today unveiled its messenger RNA (mRNA) solution, which incl...

December 27, 2021 | News

Curocell, Breaks Ground on 'CAR-T Manufacturing GMP Facility'

The GMP Facility for commercial manufacturing CAR-T Cell therapy and R&D Center for further pipeline development are constituting the 17,325 square-met...

December 24, 2021 | News

Stay Connected